Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Blin

Showing results (31-40 of 61) with videos related to

Pageof 7
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 8, 2010
Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantationFlorent Malard, Richard M Szydlo, Eolia Brissot, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 24, 2011
Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignanciesFlorent Malard, Xavier Cahu, Aline Clavert, et al.
Leukemia & Lymphoma|June 30, 2010
Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphomaAline Clavert, Steven Le Gouill, Eolia Brissot, et al.
European Journal of Haematology|January 11, 2013
Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT)Amandine Le Bourgeois, Elsa Lestang, Thierry Guillaume, et al.
Annals of Hematology|March 16, 2019
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective studySabrina Trudel, Benoît Tessoulin, Maxime Jullien, et al.
Annals of Hematology|April 29, 2020
Absence of influence of peripheral blood CD34+ and CD3+ graft cell counts on outcomes after reduced-intensity conditioning transplantation using post-transplant cyclophosphamideAlice Garnier, Thierry Guillaume, Pierre Peterlin, et al.
Annals of Hematology|March 16, 2019
Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective studyMaxime Jullien, Sabrina Trudel, Benoit Tessoulin, et al.
Blood Advances|March 31, 2021
Autoimmune hypoglycemia expands the biological spectrum of HHV8+ multicentric Castleman diseasePierre Arnautou, Martine Auclair, Soraya Fellahi, et al.
Ageing Research Reviews|March 22, 2026
Hallmarks of healthy cognitive aging: inter-individual differences in aging trajectoriesDjoher Nora Abrous, Nicolas Blin, Carl-Johan Boraxbekk, et al.
Annals of Hematology|May 18, 2020
Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real lifeClara Sortais, Anne Lok, Benoit Tessoulin, et al.
Pageof 7

Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 8, 2010
Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantationFlorent Malard, Richard M Szydlo, Eolia Brissot, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 24, 2011
Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignanciesFlorent Malard, Xavier Cahu, Aline Clavert, et al.
Leukemia & Lymphoma|June 30, 2010
Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphomaAline Clavert, Steven Le Gouill, Eolia Brissot, et al.
European Journal of Haematology|January 11, 2013
Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT)Amandine Le Bourgeois, Elsa Lestang, Thierry Guillaume, et al.
Annals of Hematology|March 16, 2019
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective studySabrina Trudel, Benoît Tessoulin, Maxime Jullien, et al.
Annals of Hematology|April 29, 2020
Absence of influence of peripheral blood CD34+ and CD3+ graft cell counts on outcomes after reduced-intensity conditioning transplantation using post-transplant cyclophosphamideAlice Garnier, Thierry Guillaume, Pierre Peterlin, et al.
Annals of Hematology|March 16, 2019
Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective studyMaxime Jullien, Sabrina Trudel, Benoit Tessoulin, et al.
Blood Advances|March 31, 2021
Autoimmune hypoglycemia expands the biological spectrum of HHV8+ multicentric Castleman diseasePierre Arnautou, Martine Auclair, Soraya Fellahi, et al.
Ageing Research Reviews|March 22, 2026
Hallmarks of healthy cognitive aging: inter-individual differences in aging trajectoriesDjoher Nora Abrous, Nicolas Blin, Carl-Johan Boraxbekk, et al.
Annals of Hematology|May 18, 2020
Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real lifeClara Sortais, Anne Lok, Benoit Tessoulin, et al.
Pageof 7